GSK ends synthetic lethality pact with Ideaya
GSK (LSE: GSK) has chosen to unwind its synthetic lethality alliance with US biotech Ideaya Biosciences (Nasdaq: IDYA), triggering a 90-day transition period in which rights to two oncology programs, IDE275 and IDE705, will return to Ideaya.
The decision was disclosed in an SEC filing, which stated that Ideaya will weigh next steps for both assets in 2026 and that its projected cash runway remains intact through 2030.
The termination brings a full close to a five-year relationship that originally aimed to advance targeted treatments for solid tumors. The companies did not disclose why GSK opted to step back from the collaboration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze